8 / 30
Cabozantinib Phase II study
Primary end-points
Lead-in stage
Randomised stage
ORR at Week 12
PFS
econdary end-points
Safety, tolerability, PFS and OS of the entire
cabozantinib treated population
Kelley RK., et al. Annals of Oncology 2017;28: 528–534.